Pre-treatment prediction of response to peginterferon plus ribavirin in chronic hepatitis C genotype 3.

ABSTRACT:

Aim

To evaluate pre-treatment factors associated with sustained virological response (SVR) in patients with hepatitis C virus (HCV) genotype 3 treated with peginterferon and ribavirin (RBV).

Methods

We retrospectively analyzed treatment naive, mono-infected HCV genotype 3 patients treated with peginterferon and RBV. Exclusion criteria included presence of other liver disease, alcohol consumption and African American or Asian ethnicity. The variables collected and compared between patients who achieved an SVR and patients who did not were as follows: gender, age, fibrosis stage, diabetes, body mass index, steatosis, INFL3 polymorphism, pre-treatment HCV-RNA, type of peginterferon, RBV dose and adherence.

Results

A total of 107 patients treated between June, 2004 and Ma

SUBMITTER: Marciano S 

PROVIDER: S-EPMC4388998 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature